GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Project Information

GlucoBeam

Grant agreement ID: 711558

DOI 10.3030/711558

Project closed

EC signature date 10 December 2015

Start date 1 February 2016

End date 31 May 2016

Funded under

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Total cost € 71 429,00

EU contribution € 50 000,00

Coordinated by

RSP SYSTEMS A/S
Denmark

Objective

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting 382 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover, GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation strategy.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• natural sciences › computer and information sciences › data science
• medical and health sciences › clinical medicine › endocrinology › diabetes
• social sciences › economics and business › business and management › business models
• medical and health sciences › health sciences › nutrition
• natural sciences › physical sciences › optics › spectroscopy

You need to log in or register to use this function

Programme(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.3. - Treating and managing disease

Topic(s)

• PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices

Call for proposal

H2020-SMEInst-2014-2015

See other projects for this call

Sub call

H2020-SMEINST-1-2015

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

RSP SYSTEMS A/S

• Net EU contribution: € 50 000,00
• Address: SIVLANDAENGET 27 C HJALLESE ; 5260 Odense S ; Denmark
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Danmark › Syddanmark › Fyn
• Region: Danmark › Syddanmark › Fyn
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 71 429,00